ClinicalTrials.gg
Active, not recruitingNCT04196465NeoChanceUpdated Oct 29, 2026

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

A Phase 2 interventional study of IMC-001 in Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer and Subjects With Resectable Liver Cancer, sponsored by Asan Medical Center. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Asan Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Liver Neoplasms with a site in Korea, Republic of — 12 open to participants now, 22 under way, 4 of them phase 3. Liver Neoplasms · Korea, Republic of.

Planned enrollment
53rd of 68
48 · median 125
Started
2019
with 4 others
Phase 2
20 of 78
1 open now
Primary completion
2028-09
later than 19 of 21 live
Registered
45th of 78
by date
Lead sponsor
6 of 78
Asan Medical Center

Among the 78 studies in Liver Neoplasms with a site in Korea, Republic of, this one is the 53rd largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2019, is one of 20 in phase 2, reaches primary completion later than 19 of the 21 other live ones, and was the 45th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

12 of the 78 studies in Liver Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Liver Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated with two cycles of neoadjuvant immune checkpoint inhibitor of IMC-001 (1 cycle = 2 weeks) followed by curative resection and be followed up consecutively.

Read the detailed description

This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated with two cycles of neoadjuvant immune checkpoint inhibitor of IMC-001 (1 cycle = 2 weeks) followed by curative resection and be followed up consecutively.

The sample size of the study is determined based on a major pathologic response rate (primary endpoint) and by using Simon's single stage design from the subjects who receive preoperative neoadjuvant therapy of IMC-001.

In each cancer cohort group, the null and alternative response rates are assumed as 5% and 20%, respectively. This provides a power of 80% when calculating the difference between major pathologic response rates of 5% and 20% in two-tailed significance level of 0.153 (Type I error[two-tailed] of 15.3%). In order to reject the null hypothesis, at least two major pathological respondents are needed among 14 assessable subjects for each cancer cohort. After choosing the margin of safety as 10%, each cancer cohort will require 16 subjects and therefore a total of 48 subjects will be enrolled into the study.

03

Conditions studied

  • Subjects With Resectable and Localized Gastric Cancer
  • Subjects With Resectable Esophageal Cancer or Liver Cancer
  • Subjects With Resectable Liver Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

\<Disease-related inclusion criteria>

  1. confirmed localized gastric adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma or clinically diagnosed hepatocellular carcinoma according to American Association for the Study of Liver Disease (AASLD) guidelines.However, in cases of hepatic carcinoma that can be clinically diagnosed according to AASLD guideline, no is performed.
  2. Curatively resectable gastric adenocarcinoma, esophageal squamous cell carcinoma or hepatocellular carcinoma

    A. Gastric adenocarcinoma: clinical stage ≥T2 or regional lymph node (N+) (AJCC 8th)

    B. Esophageal squamous cell carcinoma: clinical stage ≥T1b or N+ (AJCC 8th)

    C. Hepatocellular carcinoma: a single hepatocellular carcinoma limited to liver or 3 or less hepatocellular carcinoma limited to liver without invasion to main portal trunk

  3. The requirements for hematology, blood chemistry, and functionality in major organs are as follows (should be met within 7 days prior to the first administration of medicinal product):

    A. ≥1,000/μL

    B. count ≥75,000/μL

    C. Total ≤1.5 × (ULN) (subjects with Gilbert syndrome: bilirubin ≤ 3.0 × ULN)

    D. (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN

    E. Serum creatinine ≤1.5 × ULN or ≥50 mL/minute (creatinine clearance is first calculated by the formula of Cockcroft-Gault and in case of the value less than 50 mL/min, by collecting and examining 24-hour urine the subjects with the creatine clearance ≥50 mL/minute can be enrolled) (Refer to Supplement 1).

    F. Urine protein-creatinine ratio (UPC) ≤1 (in case of UPC >1, by collecting and examining 24-hour urine the subjects with the urine protein \<2 g/day can be enrolled)

    G. Also, in case of hepatocellular carcinoma, liver function with grade A (Refer to Supplement 2) and encephalopathy grade 0.

  4. Measurable or evaluable lesion(s) according to (RECIST) version 1.1 (Refer to Supplement 3).
  5. Tumor tissue specimen, classified as appropriate for biomarker analysis, must be provided (in case of hepatocellular carcinoma, subjects, without tissue specimen prior to the administration of investigational medicinal product, are allowed for enrollment into the study).

    \<General inclusion criteria>

  6. Aged ≥ 19 years old
  7. (ECOG) performance status 0-1
  8. Signed form
  9. In the case of fertility men and women, Those who should be using adequate measures while on study drug and for 3months following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

\<Tumor-related exclusion criteria>

  1. Curatively unresectable or disease
  2. Any prior treatment for gastric adenocarcinoma, esophageal squamous cell carcinoma or hepatocellular carcinoma. However, in case of hepatocellular carcinoma, it is possible for subjects to be enrolled into the study only if the treatment for local lesion was carried out ≥6 months ago and the treated area showed disease progression, or a curatively resectable new lesion has occurred outside the previously treated area, and other inclusion/exclusion criteria are met.
  3. Patients with history of other cancers within three years prior to the study treatment. However, patients with other cancers with less influence on their prognosis such as carcinoma in situ or thyroid papillary carcinoma, in the opinion of the investigator, can be enrolled into the study.
  4. History of hepatic encephalopathy.
  5. ascites defined as follows:

    A. When screening, the physical examination reveals ascites or

    B. Previous ascites that required treatment and continuous prevention or current ascites that require treatment.

    \< medicinal product-related exclusion criteria>

  6. History of active disease with systematic treatment (i.e. immunomodulator, , or ) required within the past 2 years. Replacement therapy (e.g. physiological corticosteroid replacement therapy due to dysfunction of thyroxine, insulin, adrenal gland, or pituitary gland, etc.) is not regarded as a form of systematic treatment and would be allowed.
  7. Diagnosis of immunodeficiency or within 7 days prior to the first administration of investigational medicinal product treatments with chronic systematic steroids (the dose equivalent to 10 mg/day of prednisone) or immunosuppressive therapy in any other forms are not permitted.
  8. History of non-infectious interstitial pneumonia requiring treatment of steroids or currently diagnosed.
  9. Any prior treatment with , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or other antibodies or drugs, specifically target co-stimulatory T cells or immune checkpoint pathways.

    \<General exclusion criteria>

  10. Any known or anaphylaxis of severeness to recombinant proteins containing monoclonal antibodies.
  11. Active infection with systematic treatment required.
  12. From the viewpoint of the investigator, medical conditions, treatments, or laboratory test abnormalities that are likely to cause confusion in clinical trial results, or that are likely to interfere with subjects' participation throughout the entire study, or that are not considered to be in the best interests of the subjects.
  13. Positive urine test or blood pregnancy test in childbearing females within 7 days prior to the first administration of investigational medicinal product.
  14. Pregnant or lactating, or during the scheduled study period of 90 days after the final administration of investigational medicinal product, subjects have a plan to have conception.
  15. Diagnosis of symptomatic congestive heart failure (i.e. Classification class II and up) or history of clinically significant heart arrhythmia that requires other antiarrhythmic drugs other than beta blockers and digoxin, or currently diagnosed or occurrence of conduction disorders (atrial fibrillation, paroxysmal supraventricular tachycardia are exceptional) within 6 months prior to the study, active coronary artery diseases, unstable angina, new occurrence of angina within 3 months before enrollment of the study, cardiac infarction within 6 months before enrollment of the study.
  16. History of (HIV 1/2 antibody)
  17. Subjects with active (HBsAg-positive or detectable HBV DNA) or (detectable HCV RNA). Patients with hepatitis B can be enrolled in the study, only if HBV DNA \<500 IU/mL (or 2500 copies/mL). Patients with positive-HCV antibody can be enrolled only if negative HCV RNA.
  18. History of allogeneic tissue/solid organ transplant.
  19. Inoculation with 28 days prior to the first administration of investigational medicinal product.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant IMC-001

    Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma

    Drug: IMC-001

Interventions

  • IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys

06

What researchers measure

Primary outcomes

  1. Major pathologic response rate

    Evaluation of major pathologic response rate (a proportion of residual viable tumor cells \<10%) after administration of pre-operative immune checkpoint inhibitor IMC-001

    Time frame: After surgical resection within 28days

Secondary outcomes

  1. The safety and feasibility

    Evaluation of safety assessed by NCI CTCAE v. 4.03 and evaluation of feasibility assessed by the occurrence of delays in prearranged surgery.

    Time frame: Within 14 days after the end of Cycle 2 (+,- 4days)

  2. R0 resection rate

    Evaluation of R0 resection rate

    Time frame: After surgical resection within 1 month

  3. Clinical tumor response rate

    Evaluation of clinical tumor response rate by RECIST v1.1

    Time frame: 1 month

  4. Clnical disease control rate

    Evaluation of clinical disease control rate by RECIST v1.1

    Time frame: 1 month

  5. Progression-free survival

    Evaluation of progression-free survival

    Time frame: 2 years

  6. Relapse-free survival

    Evaluation of relapse-free survival

    Time frame: 2 years

  7. Overall survival

    Evaluation of overall survival

    Time frame: 2 years

  8. The rates and patterns of cancer progression/relapse

    Evaluation of the rates of cancer progression/relapse

    Time frame: 2 years

  9. Patterns of cancer progression/relapse

    Evaluation of the pattern of cancer progression/relapse

    Time frame: 2 years

Other outcomes

  1. Discovery of predictive and/or prognostic biomarkers

    Discovery of predictive and/or prognostic biomarkers using pre- and post- treatment tumor tissue, blood (circulating tumor DNA, immune cells, etc.), and stool (microbiome) by performing immune profiling and genome analysis

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Bang YH, Kang D, Lee S, Kim S, Jeon I, Park E, Choi J, Song GW, Yoo MW, Song JS, Song IH, Kim YH, Kim HR, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Shim JH, Lee D, Choi J, Kim JE, Kim SY, Bae DJ, Park SR. Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study. NPJ Precis Oncol. 2026 Jul 3. doi: 10.1038/s41698-026-01571-2. Online ahead of print. PubMed 42399382 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Sep 2028, 108 months after the start.

Of 73 non-industry phase 2 interventional studies under Liver Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 103. This study's planned 108 months is above that.

Counting every sponsor, half of 87 studies reached it within 57 months; a quarter within 37 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2019
First posted
Dec 12, 2019
StartActual
Sep 9, 2019
Primary completionEst.
Sep 9, 2028was Sep 2026
CompletionEst.
Sep 26, 2028was Sep 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 9, 2026→Sep 9, 2028
Oct 29, 2026
Study completion
Sep 26, 2026→Sep 26, 2028
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Sep 9, 2026→Sep 9, 2028
    Study completion Sep 26, 2026→Sep 26, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04196465
Responsible party
Sook Ryun Park (Associated professor, Asan Medical Center) — Principal investigator
First posted
Dec 12, 2019
Start date
Sep 9, 2019
Primary completion
Sep 9, 2028 (estimated)
Completion
Sep 26, 2028 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IMC-001

Start the discussion